Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer

Zhao, JG; Ning, S; Lou, W; Yang, JC; Armstrong, CM; Lombard, AP; D'Abronzo, LS; Evans, CP; Gao, AC; Liu, CF

Gao, AC (corresponding author), Univ Calif Davis, Dept Urol Surg, Sacramento, CA 95817 USA.; Gao, AC (corresponding author), Univ Calif Davis, UC Davis Comprehens Canc Ctr, Sacramento, CA 95817 USA.; Gao, AC (corresponding author), VA Northern Calif Hlth Care Syst, Sacramento, CA USA.; Liu, CF (corresponding author), Univ Calif Davis, Res 3 Bldg,Suite 1300,4645 2nd Ave, Sacramento, CA 95817 USA.

MOLECULAR CANCER THERAPEUTICS, 2020; 19 (8): 1708

Abstract

The next-generation antiandrogen drugs, XTANDI (enzalutamide), ZYTIGA (abiraterone acetate), ERLEADA (apalutamide) and NUBEQA (darolutamide) extend su......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索